These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 16997556)

  • 21. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases.
    Thaimattam R; Daga PR; Banerjee R; Iqbal J
    Bioorg Med Chem; 2005 Aug; 13(15):4704-12. PubMed ID: 15914012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of thienopyridines as Src-family selective Lck inhibitors.
    Abbott L; Betschmann P; Burchat A; Calderwood DJ; Davis H; Hrnciar P; Hirst GC; Li B; Morytko M; Mullen K; Yang B
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1167-71. PubMed ID: 17234410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck.
    Gommermann N; Buehlmayer P; von Matt A; Breitenstein W; Masuya K; Pirard B; Furet P; Cowan-Jacob SW; Weckbecker G
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3628-31. PubMed ID: 20483608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
    Farag AK; Elkamhawy A; Londhe AM; Lee KT; Pae AN; Roh EJ
    Eur J Med Chem; 2017 Dec; 141():657-675. PubMed ID: 29107425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
    Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
    Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection.
    Borhani DW; Calderwood DJ; Friedman MM; Hirst GC; Li B; Leung AK; McRae B; Ratnofsky S; Ritter K; Waegell W
    Bioorg Med Chem Lett; 2004 May; 14(10):2613-6. PubMed ID: 15109663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
    Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
    J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
    Huang S; Li R; Connolly PJ; Emanuel S; Middleton SA
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4818-21. PubMed ID: 16870444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of pyridopyrimidines as potent Akt1/2 inhibitors.
    Wu Z; Hartnett JC; Neilson LA; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Hartman GD; Bilodeau MT
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1274-9. PubMed ID: 18249537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and evaluation of 3-phenylpyrazolo[3,4-d]pyrimidine-peptide conjugates as Src kinase inhibitors.
    Kumar A; Wang Y; Lin X; Sun G; Parang K
    ChemMedChem; 2007 Sep; 2(9):1346-60. PubMed ID: 17530729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure of human Fyn kinase domain complexed with staurosporine.
    Kinoshita T; Matsubara M; Ishiguro H; Okita K; Tada T
    Biochem Biophys Res Commun; 2006 Aug; 346(3):840-4. PubMed ID: 16782058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.
    Snow RJ; Abeywardane A; Campbell S; Lord J; Kashem MA; Khine HH; King J; Kowalski JA; Pullen SS; Roma T; Roth GP; Sarko CR; Wilson NS; Winters MP; Wolak JP; Cywin CL
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3660-5. PubMed ID: 17499505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of CH/pi hydrogen bonds in rational drug design: An ab initio fragment molecular orbital study to leukocyte-specific protein tyrosine (LCK) kinase.
    Ozawa T; Tsuji E; Ozawa M; Handa C; Mukaiyama H; Nishimura T; Kobayashi S; Okazaki K
    Bioorg Med Chem; 2008 Dec; 16(24):10311-8. PubMed ID: 18977146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
    Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2009 Jan; 17(1):284-94. PubMed ID: 19010686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and SAR of 2-phenoxypyridines as novel c-Jun N-terminal kinase inhibitors.
    Song X; Chen W; Lin L; Ruiz CH; Cameron MD; Duckett DR; Kamenecka TM
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7072-5. PubMed ID: 22004719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cee VJ; Chai L; Deak HL; Epstein LF; Faust T; Gallant P; Geuns-Meyer SD; Gore A; Gu Y; Henkle B; Hodous BL; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; Masse CE; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; White RD; Zhao H; Zhu L; Zhu X
    J Med Chem; 2006 Sep; 49(19):5671-86. PubMed ID: 16970394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.